<DOC>
	<DOCNO>NCT02215356</DOCNO>
	<brief_summary>This randomise , multi-center , control trial design assess efficacy safety icotinib concurrent radiotherapy versus chemotherapy concurrent radiotherapy non-small cell lung cancer</brief_summary>
	<brief_title>Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This randomise , multi-center , control trial design assess efficacy safety icotinib concurrent radiotherapy versus etoposide/cisplatin concurrent radiotherapy stage III non-small cell lung cancer EGFR 19/21 Mutation , primary endpoint progression-free survival</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Unresectable stage IIIA / IIIB nonsmall cell lung cancer EGFR 19/21 mutation No previous systemic anticancer therapy Measurable lesion accord RECIST least one measurable lesion previously irradiate , unless disease progression document site ECOG Performance Status 0 1 Prior treatment antiEGFR ( epidermal growth factor receptor ) monoclonal antibody small molecular compound therapy gefitinib , erlotinib cetuximab Evidence clinically active Interstitial Lung Diseases ( patient chronic , stable , radiographic change asymptomatic need exclude ) Known severe hypersensitivity icotinib excipients product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>